에 대한 최신 뉴스 Align Tech (NASDAQ:ALGN) 주식

Align Tech

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Earnings

News

Guidance

Health Care

After-Hours Center

Movers

ALGN

치과 교정에 사용되는 3D 디지털 스캐너와 인비절라인(Invisalign) 투명 교정 장치를 생산하는 미국 제조업체 얼라인 테크놀로지(NASDAQ:ALGN)의 주가는 회사가 2분기 재무 결과를 보고하고 약한 가이던스를 발표한 후 수요일 시간외 세션에서 하락했다.

얼라인 테크놀로지는 약한 2분기 매출 실적과 3분기 가이던스 발표 후 주가 하락

BALL

BNTX

ENPH

FSLR

MBLY

RIVN

FLSR

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 게임스탑(NYSE:GME)의 주가는 연간 주주총회 이후 지난주에 18.61% 하락했으며, CEO 라이언 코헨은 비용 절감을 통해 수익성을 향한 전략적 전환을 강조했다.

게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)

Align Technology Inc

ALIGN TECHNOLOGY ORD

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

EXAS

ILMN

MRNA

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

WIIM

Align Technology shares are trading higher after Piper Sandler maintained an Overweight rating and $315 price target on the stock.

Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Align Tech, revealing an average target of $325.0, a high estimate of $350.00, and a low estimate of $310.00. This current average has decreased by 7.07% from the previous average price target of $349.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1726243234_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Align Tech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$375.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Align Tech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Align Tech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Align Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Align Tech's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Align Tech analyst ratings.</a>
<h2>Delving into Align Tech's Background</h2>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
<h3>Align Tech: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Align Tech displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 2.63%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Align Tech's net margin is impressive, surpassing industry averages. With a net margin of 9.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Align Tech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Align Tech's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Align Tech Stock: Analyst Perspectives (7 Ratings)

Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and maintains $315 price target.

Price Target

Piper Sandler Maintains Overweight on Align Tech, Maintains $315 Price Target

COST

Align Technology Pilots U.S. Invisalign Treatment Promotional Program For Members On Costco.com

Whales with a lot of money to spend have taken a noticeably bullish stance on Align Tech.
Looking at options history for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $229,860 and 3, calls, for a total amount of $341,228.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $280.0 for Align Tech over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Align Tech options trades today is 127.12 with a total volume of 540.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Align Tech's big money trades within a strike price range of $160.0 to $280.0 over the last 30 days.
<h3>Align Tech Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722024086_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.1</td>
<td>$19.3</td>
<td>$20.5</td>
<td>$240.00</td>
<td>$195.0K</td>
<td style="text-align: right;">177</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.5</td>
<td>$9.0</td>
<td>$9.75</td>
<td>$280.00</td>
<td>$117.0K</td>
<td style="text-align: right;">239</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$40.1</td>
<td>$37.2</td>
<td>$40.2</td>
<td>$260.00</td>
<td>$80.4K</td>
<td style="text-align: right;">172</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$5.2</td>
<td>$4.3</td>
<td>$5.2</td>
<td>$230.00</td>
<td>$51.4K</td>
<td style="text-align: right;">130</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$23.2</td>
<td>$22.8</td>
<td>$22.8</td>
<td>$220.00</td>
<td>$38.7K</td>
<td style="text-align: right;">74</td>
<td style="text-align: right;">18</td>
</tr>
</tbody>
</table>

<h3>About Align Tech</h3>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
After a thorough review of the options trading surrounding Align Tech, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Align Tech</h3>
<ul>
<li>Trading volume stands at 950,728, with ALGN's price down by -2.36%, positioned at $220.72.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>What The Experts Say On Align Tech</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $326.0.
<ul>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Align Tech with a target price of $310. </li>
<li>Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Align Tech, targeting a price of $325. </li>
<li>Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Align Tech with a target price of $330. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Align Tech, targeting a price of $315. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Align Tech with a target price of $350. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Align Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Markets

Align Tech Unusual Options Activity

Morgan Stanley analyst Erin Wright maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $328 to $310.

Morgan Stanley Maintains Overweight on Align Tech, Lowers Price Target to $310

Financial giants have made a conspicuous bullish move on Align Tech. Our analysis of options history for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $691,540, and 3 were calls, valued at $98,670.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $300.0 for Align Tech, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Align Tech's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Align Tech's significant trades, within a strike price range of $240.0 to $300.0, over the past month.
<h3>Align Tech Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721916270_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$8.0</td>
<td>$7.9</td>
<td>$8.0</td>
<td>$240.00</td>
<td>$206.4K</td>
<td>1.0K</td>
<td style="text-align: right;">347</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$8.7</td>
<td>$4.9</td>
<td>$7.4</td>
<td>$240.00</td>
<td>$180.8K</td>
<td>1.0K</td>
<td style="text-align: right;">589</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$13.7</td>
<td>$11.6</td>
<td>$13.4</td>
<td>$250.00</td>
<td>$100.5K</td>
<td>47</td>
<td style="text-align: right;">221</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$9.3</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$240.00</td>
<td>$99.1K</td>
<td>1.0K</td>
<td style="text-align: right;">824</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$12.6</td>
<td>$8.8</td>
<td>$10.8</td>
<td>$250.00</td>
<td>$78.2K</td>
<td>47</td>
<td style="text-align: right;">73</td>
</tr>
</tbody>
</table>

<h3>About Align Tech</h3>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
In light of the recent options history for Align Tech, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Align Tech</h3>
<ul>
<li>With a trading volume of 256,644, the price of ALGN is down by -3.53%, reaching $236.16.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>What The Experts Say On Align Tech</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $330.0.
<ul>
<li>An analyst from Piper Sandler persists with their Overweight rating on Align Tech, maintaining a target price of $330. </li>
<li>Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Align Tech with a target price of $315. </li>
<li>An analyst from Stifel persists with their Buy rating on Align Tech, maintaining a target price of $350. </li>
<li>An analyst from Baird has decided to maintain their Outperform rating on Align Tech, which currently sits at a price target of $325. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Align Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About Align Tech

Stifel analyst Jonathan Block maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Buy and lowers the price target from $400 to $350.

Stifel Maintains Buy on Align Tech, Lowers Price Target to $350

Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $330 to $315.

Piper Sandler Maintains Overweight on Align Tech, Lowers Price Target to $315

Align Technology shares are trading lower following soft Q3 guidance.

Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares are trading lower in Wednesday&#8217;s after-hours session after the company reported second-quarter financial results and <a href="https://www.benzinga.com/pressreleases/24/07/b39942047/align-technology-announces-second-quarter-2024-financial-results">issued soft guidance</a>.
<ul>
<li>Q2 Revenue: $1.03 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.04 billion</li>
</ul>
<ul>
<li>Q2 EPS: $2.41, versus estimates of $2.30</li>
</ul>
Total revenue was up 2.6% on a year-over-year basis after being unfavorably impacted by foreign exchange of approximately&nbsp;$11.6 million&nbsp;or&nbsp;1.1%. 
Align, which sells the well-known Invisalign clear aligner system, said clear aligner revenues were down 0.1% year-over-year to $831.7 million in the quarter. Imaging systems and CAD/CAM services revenue totaled $196.8 million, up 16.1% on a year-over-year basis.
&#8220;In Q2, the number of doctors submitting teen or younger patient case starts was up 8% year-over-year, led by continued strength from doctors treating young kids also known as &#8216;growing patients.&#8217; Our Q2 results also reflect a record number of doctors submitting cases, and record doctors shipped to for the quarter,&#8221; said Joe Hogan, president and CEO of Align.
As of June 30, the company had $782.1 million in cash, cash equivalents and marketable securities, as well as $300 million&nbsp;available under a revolving line of credit.
See Also: <a href="https://www.benzinga.com/news/earnings/24/07/39943178/ford-q2-earnings-highlights-revenue-beat-eps-miss-transit-vans-hit-record-ev-sales-fall-37">Ford Q2 Earnings Highlights: Revenue Beat, EPS Miss, Transit Vans Hit Record, EV Sales Fall 37%</a>
Guidance: Align sees third-quarter revenue in the range of $980 million to $1 billion versus estimates of $1.03 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Align anticipates full-year 2024 revenue growth of 4% to 6%.
The company noted it expects clear aligner volume to be down in the third quarter due to seasonality trends. Align also expects systems and services revenue to be down sequentially because of third-quarter seasonality.
ALGN Price Action: Align shares were down 4.20% after hours at $234.51 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Align.

Align Technology Stock Drops On Q2 Earnings: What Investors Need To Know

Third quarter 2024 outlook:
For Q3'24, we are providing the following business outlook:
•We expect our Q3 worldwide revenues to be in the range of $980M to $1,000M
•We expect Clear Aligner volume to be down sequentially as a result of Q3 seasonality, and Clear Aligner ASPs to be down sequentially, primarily due to foreign exchange and product mix
•We also expect Systems and Services revenues to be down sequentially because of Q3 seasonality
•We expect our Q3'24 GAAP operating margin to be below Q3'23 GAAP operating margin and Q3'24 non-GAAP operating margin to be flat to Q3'23 non-GAAP operating margin

Align Technology Sees Q3 2024 Revenue $980M-$1B Vs $1.03B Estimate

Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.30 by 4.78 percent. The company reported quarterly sales of $1.03 billion which missed the analyst consensus estimate of $1.04 billion by 0.71 percent. This is a 2.69 percent increase over sales of $1.00 billion the same period last year.

Earnings Beats

Earnings Misses

Align Tech Q2 2024 Adj EPS $2.41 Beats $2.30 Estimate, Sales $1.03B Miss $1.04B Estimate

Early Access Registration Opens Today; Available To Customers Later This Year

Align Technology Introduces iTero Design Suite For In-Practice 3D Printing Of Models, Bite Splints, And Restorations

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$75.00</td>
<td>$68.9K</td>
<td>5.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$170.00</td>
<td>$121.7K</td>
<td>4.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>EVH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$28.7K</td>
<td>3.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$240.00</td>
<td>$72.6K</td>
<td>158</td>
<td>867</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$225.00</td>
<td>$25.9K</td>
<td>509</td>
<td>343</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.00</td>
<td>$100.5K</td>
<td>9.3K</td>
<td>313</td>
</tr>
<tr>
<td>ZVRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.50</td>
<td>$38.7K</td>
<td>3.8K</td>
<td>253</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$550.00</td>
<td>$77.4K</td>
<td>316</td>
<td>250</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$33.0K</td>
<td>502</td>
<td>150</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$23.00</td>
<td>$69.0K</td>
<td>1.1K</td>
<td>103</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on August 16, 2024. This event was a transfer of 811 contract(s) at a $75.00 strike. This particular put needed to be split into 47 different trades to become filled. The total cost received by the writing party (or parties) was $68.9K, with a price of $85.0 per contract. There were 5564 open contracts at this strike prior to today, and today 2101 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with neutral sentiment. It expires in 115 day(s) on November 15, 2024. Parties traded 234 contract(s) at a $170.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $121.7K, with a price of $520.0 per contract. There were 4997 open contracts at this strike prior to today, and today 1291 contract(s) were bought and sold. 
• For EVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), we notice a call option sweep that happens to be bearish, expiring in 178 day(s) on January 17, 2025. This event was a transfer of 87 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $330.0 per contract. There were 3588 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bullish sentiment. It expires in 87 day(s) on October 18, 2024. Parties traded 330 contract(s) at a $240.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $72.6K, with a price of $220.0 per contract. There were 158 open contracts at this strike prior to today, and today 867 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option sweep with bearish sentiment. It expires in 3 day(s) on July 26, 2024. Parties traded 54 contract(s) at a $225.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $480.0 per contract. There were 509 open contracts at this strike prior to today, and today 343 contract(s) were bought and sold. 
• Regarding NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we observe a call option trade with bullish sentiment. It expires in 178 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $100.5K, with a price of $670.0 per contract. There were 9360 open contracts at this strike prior to today, and today 313 contract(s) were bought and sold. 
• For ZVRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>), we notice a call option sweep that happens to be bearish, expiring in 115 day(s) on November 15, 2024. This event was a transfer of 250 contract(s) at a $7.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.7K, with a price of $155.0 per contract. There were 3801 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option trade that happens to be bullish, expiring in 3 day(s) on July 26, 2024. This event was a transfer of 90 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $77.4K, with a price of $860.0 per contract. There were 316 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we observe a put option trade with bullish sentiment. It expires in 178 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $9.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $220.0 per contract. There were 502 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with neutral sentiment. It expires in 332 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $23.00 strike. The total cost received by the writing party (or parties) was $69.0K, with a price of $690.0 per contract. There were 1193 open contracts at this strike prior to today, and today 103 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IOVA

NVAX

ZVRA

10 Health Care Stocks Whale Activity In Today's Session

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $341.43, a high estimate of $375.00, and a low estimate of $300.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.51%. 
<img src="https://www.benzinga.com/files/images/story/2024/1721656852_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Align Tech is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$360.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$333.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Align Tech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Align Tech compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Align Tech's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Align Tech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Align Tech analyst ratings.</a>
<h2>About Align Tech</h2>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
<h3>Key Indicators: Align Tech's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Align Tech's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 5.76%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Align Tech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.53%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Align Tech's ROA stands out, surpassing industry averages. With an impressive ROA of 1.72%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Align Tech's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 7 Analyst Evaluations For Align Tech

Baird analyst Jeff Johnson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and lowers the price target from $370 to $325.

Baird Maintains Outperform on Align Tech, Lowers Price Target to $325

Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and maintains $330 price target.

Piper Sandler Maintains Overweight on Align Tech, Maintains $330 Price Target

Over the past twelve months, 10 large-cap stocks have underperformed all others. Here's this week's list of the top 10 worst performing large-caps.

Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers

Align to pay $27.5M to SmileDirectClub clients as antitrust lawsuit nears settlement

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here's an updated look at the top 10 worst performing large-caps with their one-year price returns.

Large-Cap Stocks In Trouble - Sunday, Sept. 1

Align Technology reports new regional leadership roles

Fidelity Growth Strategies Fund Q2 2024 Review

50 stocks to invest during the bull steepening – Part 2

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Align Tech (ALGN – Research Report) today and set a price target of $350.00. The ...

Stifel Nicolaus Reaffirms Their Buy Rating on Align Tech (ALGN)

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here's an updated look at the top 10 worst performing large-caps along with their one-year price returns.

Large-Cap Stocks In Trouble - Sunday, Sept. 8

Piper Sandler analyst Jason Bednar maintained a Buy rating on Align Tech (ALGN – Research Report) today and set a price target of $315.00. The comp...

Align Tech (ALGN) Gets a Buy from Piper Sandler

BlackRock Innovation And Growth Term Trust Q2 2024 Commentary

ASMIY

ASMXF

BIGZ

BRBR

CACI

CELH

CSGP

CWST

DXCM

ELAN

EXLS

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FRPT

FSMD

FSTA

FTEC

FUTY

FVAL

GKOS

GMED

HSIC

IDXX

INTC

JAZZ

LULU

MASI

MPWR

ONEQ

PAYC

PCTY

PINS

PLTR

PODD

POST

RGEN

SAIA

SDCCQ

SOLV

SPOT

Press Releases

Align Technology to Announce Second Quarter 2024 Results on July 24, 2024

Operation Smile Announces Align Technology as Title Sponsor of International Student Leadership Conference

Align Technology Introduces iTero™ Design Suite, Enabling Intuitive Design Capabilities for In-Practice 3D Printing to Boost Practice Efficiency

Align Technology Announces Second Quarter 2024 Financial Results

Align Technology Pilots U.S. Invisalign® Treatment Promotional Program on Costco.com

Align Technology Announces New Regional Leadership Roles

Align Technology to Speak at Upcoming Financial Conference

Court Grants Preliminary Approval of Settlement to Resolve All Outstanding Shareholder Derivative Litigation Involving Align

Comments

Align Tech

뉴스

에 대한 최신 뉴스 Align Tech (NASDAQ:ALGN) 주식

목요일, 7월 25, 2024

일요일, 6월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌